The Genitourinary Cancer Channel

Explore the latest updates, including expert interviews and features
Latest videos VJSessions Subtypes Topics Conferences Features Editorial Board

Welcome to the Genitourinary (GU) Cancer Channel!

Explore the latest updates presented at major international congresses in the form of video interviews, podcasts and roundtable discussions featuring members of our expert Editorial Board.

Exciting advances are being made in the field of genitourinary cancer, including checkpoint inhibitor treatments, new non-steroidal anti-androgens, chemoimmunotherapy combinations and predictive biomarkers.

GU Cancer Videos by Subtype

Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Penile Cancer
6:29
Should polygenic risk scores be used to risk-stratify the use of PSA-screening in prostate cancer?
Andrew Vickers • 11 May 2022
8:41
MRI-targeted biopsies and overdiagnosis in prostate cancer
Andrew Vickers • 11 May 2022
4:28
Update on PETRA trial investigating a next-generation PARP1 select inhibitor
Timothy Yap • 13 Apr 2022
3:30
Radionuclide conjugates 225Ac-J591 and 177Lu-PSMA-I&T for mCRPC
Scott Tagawa • 11 Apr 2022
View All Videos
2:08
CORE1 trial: CG0070 plus pembrolizumab for BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li • 23 May 2022
1:55
Durvalumab monotherapy for patients with BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li • 23 May 2022
1:45
Mechanism of action of the adenovirus oncolytic virus CG0070 plus pembrolizumab in bladder cancer
Roger Li • 23 May 2022
1:38
Future indications for MRx0518
Alex Stevenson • 5 Apr 2022
View All Videos
0:18
Future research directions for the novel PD-1 and CTLA-4 bispecific checkpoint inhibitor, MEDI5752
Ben Tran • 21 Apr 2022
1:31
MRx0518 combination therapy meets primary efficacy endpoint ahead of enrollment completion
Alex Stevenson • 5 Apr 2022
1:14
Anti-CAIX immune restoring CAR T-cells reverse immunosuppressive TME
Yufei Wang • 11 Apr 2022
0:53
Unanswered questions in the management of clear cell RCC
Mehmet Bilen • 19 Feb 2022
View All Videos
7:05
TRISST: MRI versus FDG-PET-CT for the treatment of testicular cancer
Tahlita Zuiverloon • 15 Jul 2021
3:40
Surgery in metastatic germ cell tumors to reduce disease burden and improve long-term outcomes
Peter Albers • 8 Jul 2021
3:34
Benefits of circulating miRNAs for follow-up of patients with seminoma
Matthew Murray • 1 Jul 2021
1:12
miR-371a-3p microRNA panel alone is sufficient for diagnosis and monitoring
Matthew Murray • 1 Jul 2021
View All Videos
3:18
RCC & penile cancer at ASCO GU: KN-564, NeoAvAx & PERICLES
Jen-Jane Liu • 18 Feb 2022
5:44
Long-term outcomes of DSNB for cN0 penile cancer
Edoardo Pozzi • 10 Jul 2021
2:06
c-MET receptor-targeted fluorescence for image-guided surgery in PSCC
Hielke-Martijn De Vries • 7 Jul 2021
3:14
Factors impacting additional tumour-bearing lymph nodes at completion ILND after positive DSNB
Hielke-Martijn De Vries • 7 Jul 2021
View All Videos

Topics

Trial Updates
Molecular Profiling
Immuno-Oncology
Diagnosis
Imaging
2:08
CORE1 trial: CG0070 plus pembrolizumab for BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li • 23 May 2022
1:55
Durvalumab monotherapy for patients with BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li • 23 May 2022
4:28
Update on PETRA trial investigating a next-generation PARP1 select inhibitor
Timothy Yap • 13 Apr 2022
1:38
Future indications for MRx0518
Alex Stevenson • 5 Apr 2022
View All Videos
6:29
Should polygenic risk scores be used to risk-stratify the use of PSA-screening in prostate cancer?
Andrew Vickers • 11 May 2022
3:42
ctDNA level variation as an early predictor of survival in patients with mCRPC
Vincenza Conteduca • 15 Feb 2022
0:53
Unanswered questions in the management of clear cell RCC
Mehmet Bilen • 19 Feb 2022
0:57
Is ctDNA a good biomarker for advanced prostate cancer?
Vincenza Conteduca • 15 Feb 2022
View All Videos
2:08
CORE1 trial: CG0070 plus pembrolizumab for BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li • 23 May 2022
1:55
Durvalumab monotherapy for patients with BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li • 23 May 2022
1:45
Mechanism of action of the adenovirus oncolytic virus CG0070 plus pembrolizumab in bladder cancer
Roger Li • 23 May 2022
0:18
Future research directions for the novel PD-1 and CTLA-4 bispecific checkpoint inhibitor, MEDI5752
Ben Tran • 21 Apr 2022
View All Videos
6:29
Should polygenic risk scores be used to risk-stratify the use of PSA-screening in prostate cancer?
Andrew Vickers • 11 May 2022
8:41
MRI-targeted biopsies and overdiagnosis in prostate cancer
Andrew Vickers • 11 May 2022
3:42
ctDNA level variation as an early predictor of survival in patients with mCRPC
Vincenza Conteduca • 15 Feb 2022
0:57
Is ctDNA a good biomarker for advanced prostate cancer?
Vincenza Conteduca • 15 Feb 2022
View All Videos
8:41
MRI-targeted biopsies and overdiagnosis in prostate cancer
Andrew Vickers • 11 May 2022
0:57
Is ctDNA a good biomarker for advanced prostate cancer?
Vincenza Conteduca • 15 Feb 2022
2:59
Using artificial intelligence to improve cancer care
Irbaz Riaz • 19 Feb 2022
0:25
PSMA PET scans for prostate cancer
Neil Fleshner • 17 Feb 2022
View All Videos

Conferences

GU Cancers 2022
ESMO 2021
EAU 2021
ASCO 2021
AACR 2021
GU Cancers 2021
3:42
ctDNA level variation as an early predictor of survival in patients with mCRPC
Vincenza Conteduca • 15 Feb 2022
0:53
Unanswered questions in the management of clear cell RCC
Mehmet Bilen • 19 Feb 2022
2:20
Future of PARP inhibitors for urothelial carcinoma
Massimo Di Maio • 3 Mar 2022
2:41
Results from URO-12 trial of niraparib maintenance therapy for advanced urothelial carcinoma
Massimo Di Maio • 3 Mar 2022
View All Videos
3:45
Impacts of COVID-19 infection on patients with urological cancers undergoing surgery
Chuanyu Gao • 7 Jul 2021
3:04
Benefits of T1 substaging for NMIBC
Christiaan De Jong • 21 Jul 2021
4:19
Novel biomarkers for outcomes identified in BCG-treated T1HG bladder cancer
Christiaan De Jong • 21 Jul 2021
3:27
Improving anti-PD-1/PD-L1 therapy for localized bladder cancer
Christiaan De Jong • 21 Jul 2021
View All Videos
4:42
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients with prostate cancer
Frédéric Pouliot • 4 Jun 2021
4:45
PrE0807: neoadjuvant nivolumab/lirilumab in cisplatin ineligible patients with MIBC
Petros Grivas • 11 Jun 2021
5:49
JAVELIN Bladder 100 trial updates from ASCO 2021
Petros Grivas • 11 Jun 2021
10:12
Trial updates in prostate cancer from ASCO 2021: VISION, PEACE1, & SWOG S1216
Pedro Barata • 8 Jun 2021
View All Videos
3:07
PSMA dRT: PSMA PET/CT before radiotherapy in prostate cancer
Jeremie Calais • 22 Apr 2021
6:49
RAMP: Phase Ib study of rucaparib & enzalutamide in mCRPC
Arpit Rao • 19 Apr 2021
4:38
Clinical utility of liquid biopsies in prostate cancer
Arpit Rao • 19 Apr 2021
3:53
Upcoming advances in prostate cancer: PARPi, CDK4/6, lutetium PSMA therapy & CAR-T approaches
Arpit Rao • 19 Apr 2021
View All Videos
1:50
Current treatment landscape of seminoma
Siamak Daneshmand • 18 Feb 2021
3:05
CA 125, CA19-9 and CEA: tumor markers in bladder cancer
Siamak Daneshmand • 18 Feb 2021
3:18
SEMS: surgery as first-line therapy for seminoma
Siamak Daneshmand • 18 Feb 2021
3:43
The history of biomarkers in the treatment of prostate cancer
Howard Scher • 18 Feb 2021
View All Videos
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals